Turning the key on p53

Nature

Volumn 427, Issue 6977, 2004, Pages 789-790

  Lane, David P ^a,b   Fischer, Peter M ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION; ONCOLOGY; TUMORS;

ANTI-TUMOR DUTIES; NATURAL DEFENCES;

PROTEINS;

ANTINEOPLASTIC AGENT; ONCOPROTEIN; PEPTIDE; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR;

CANCER; MEDICINE;

ANIMAL; ANTINEOPLASTIC ACTIVITY; BINDING SITE; CANCER INHIBITION; CELL CYCLE; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFECT; DRUG POTENTIATION; GENE MUTATION; GENE THERAPY; GENETICS; HOST RESISTANCE; HUMAN; KNOCKOUT GENE; METABOLISM; MOUSE; NEOPLASM; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SHORT SURVEY;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL CYCLE; DRUG DESIGN; HUMANS; MICE; NEOPLASMS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 1542319132     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/427789a     Document Type: Short Survey

References (11)

1. Lane, D. P. & Crawford, L. V. Nature 278, 261-263 (1979).
2. Vousden, K. H. & Lu, X. Nature Rev. Cancer 2, 594-604 (2002).
3. Surendran, A. Nature Med. 10, 9 (2004).
4. Snyder, E. L. et al. PLoS Biol. doi: 10.1371/journal.pbio.0020036 (2004).
5. Vassilev, L. T. et al. Science 303, 844-848 (2004).
6. Gudkov, A. V. & Komarova, E. A. Nature Rev. Cancer 3, 117-129 (2003).
7. Iwakuma, F. & Lozano, G. Mol. Cancer Res. 1, 993-1000 (2003).
8. Montes de Oca Luna, R., Wagner, D. S. & Lozano, G. Nature 378, 203-206 (1995).
9. Chene, P. Nature Rev. Cancer 3, 102-109 (2003).
10. Mendrysa, S. M. et al. Mol. Cell. Biol. 23, 462-473 (2003).
11. O'Leary, K. A. et al. Mol. Cell. Biol. 24, 186-191 (2004).